drugset / Trial / NCT00043927

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

NCT00043927

Phase 3 Completed 760 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will gather and compare data about the effectiveness and safety of two different treatments for extensive Small Cell Lung Cancer (SCLC) in patients who have not received previous chemotherapy. One treatment will use an investigational drug in combination with an FDA approved chemotherapy. The other treatment will use a combination of two FDA approved chemotherapy drugs.

Timeline

Start
2001-04
Primary completion
2004-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Etoposide Small molecule
Subject Topotecan Small molecule Oral
Background Cisplatin Other / unclassified